

Review

Open Access

Transcriptional regulation of lipid metabolism by fatty acids: a key determinant of pancreatic β -cell function

Zahra Fatehi-Hassanabad and Catherine B Chan*

Address: Department of Biomedical Sciences, University of Prince Edward Island, 550 University Avenue, Charlottetown, PE C1A 4P3 Canada

Email: Zahra Fatehi-Hassanabad - zfatehi@upei.ca; Catherine B Chan* - cchan@upei.ca

* Corresponding author

Published: 05 January 2005

Received: 20 October 2004

Nutrition & Metabolism 2005, **2**:1 doi:10.1186/1743-7075-2-1

Accepted: 05 January 2005

This article is available from: <http://www.nutritionandmetabolism.com/content/2/1/1>

© 2005 Fatehi-Hassanabad and Chan; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Optimal pancreatic β -cell function is essential for the regulation of glucose homeostasis in both humans and animals and its impairment leads to the development of diabetes. Type 2 diabetes is a polygenic disease aggravated by environmental factors such as low physical activity or a hypercaloric high-fat diet.

Results: Free fatty acids represent an important factor linking excess fat mass to type 2 diabetes. Several studies have shown that chronically elevated free fatty acids have a negative effect on β -cell function leading to elevated insulin secretion basally but with an impaired response to glucose. The transcription factors PPAR α , PPAR γ and SREBP-1c respond to changing fat concentrations in tissues, thereby coordinating the genomic response to altered metabolic conditions to promote either fat storage or catabolism. These transcription factors have been identified in β -cells and it appears that each may exert influence on β -cell function in health and disease.

Conclusion: The role of the PPARs and SREBP-1c as potential mediators of lipotoxicity is an emerging area of interest.

Introduction

Fatty acids are physiologically important both structurally, as components of phospholipids and glycolipids, as well as functionally, as fuel molecules. Metabolites of fatty acids, such as leukotrienes or prostaglandins, act as potent mediators in many biological processes. Fatty acids provide energy [1,2], particularly in the fasted state (Figure 1), but abnormalities in the metabolism of fatty acids can contribute to the pathogenesis of obesity and type 2 diabetes.

Type 2 diabetes and free fatty acids

Diabetes affects 6 % of the adult population and, with a growth rate of 6% per year, it is estimated that 200 to 300 million people worldwide will be afflicted by the end of

this decade [3]. Type 1 diabetes, which accounts for < 10 % of all cases of diabetes [4], results from autoimmune-mediated destruction of pancreatic β -cells. The destruction may occur over months to years and can result in complete loss of the endogenous insulin supply and therefore results in exogenous insulin dependency.

Type 2 diabetes, which accounts for 90 to 95 % of diabetes cases worldwide, is a heterogeneous disorder and its prevalence is rising. Type 2 diabetes is accompanied by chronic insulin resistance and a progressive decline in β -cell function [5]. Obesity is a major risk factor for the development of type 2 diabetes [6] and is believed to confer increased risk through obesity-associated insulin resistance [7]. Type 2 diabetes is often associated with




Figure 1
Schematic diagram of fatty acid metabolism in the fasted state. Counter-regulatory hormones such as catecholamines act on adipocytes to increase lipolysis via hormone-sensitive lipase (HSL). Circulating FFA enter the cell and are converted to acyl CoAs, catalyzed by acyl CoA synthase (ACS). Acyl CoA enter the mitochondria via carnitine palmitoyl transferase-I (solid square) and enter the β-oxidation cycle (stippled circle) to produce acetyl CoA that is then available for further metabolism in the TCA cycle, leading to increased ATP and substrates for anaplerosis. In the β-cell, acyl CoA also participate as signalling molecules to promote insulin secretion (see text).

hypertriglyceridemia or increased circulating concentrations of free fatty acids (FFA) [8]. Therefore, type 2 diabetes can be considered a lipid disorder as well as a disease of glucose intolerance [9].

Metabolism of fatty acids in the beta cell and insulin secretion

Fatty acids, not glucose, are the major endogenous energy source for unstimulated islets [10]. This is consistent with the observation that although islets contain little glycogen, they maintain high rates of oxygen consumption in the absence of glucose [11]. Stimulation of islets by glucose diminishes fatty acid oxidation and increases total respiration [12]. Thus, rising post-prandial plasma glucose shifts the β-cells from fatty acids to glucose as an oxidative fuel. However, plasma concentrations of other nutrients such as FFA and amino acids can modulate the process of glucose-induced insulin secretion [9]. The plasma levels of nutrient metabolites vary with dietary composition. Thus, feeding behavior plays an important role in the control of islet β-cell function [13,14].

Short-term (2–6 hours) elevation of the plasma FFA concentration in human subjects [15] and animals [16,17] enhances while an acute decrease inhibits glucose-stimulated insulin secretion [15,18]. Following lipid infusion or ingestion of a mixed meal, the plasma FFA concentration rises and FFA diffuse into the β-cells [19]. Within the cytosol, fatty acids are converted to their fatty acyl CoA derivatives (Figure 1), which in turn augment insulin secretion via different signalling mechanisms: increased formation of phosphatidic acid and diacylglycerol, which directly and indirectly (through activation of protein kinase C) enhance exocytosis of insulin stored within secretory granules; stimulation of endoplasmic reticulum Ca²⁺-adenosine triphosphatase, leading to an increase in intracellular calcium concentration and augmentation of insulin secretion; and closure of the K⁺-ATP channel with resultant depolarization of the β-cell membrane, which causes an increase in intracellular Ca²⁺ and stimulation of exocytosis of insulin-containing granules [21]. In addition to being oxidized, glucose can be metabolized through anaplerotic processes to increase malonyl CoA

concentrations in the β -cell. Malonyl CoA inhibits CPT-I, thus impairing the transport of fatty acyl CoAs into the mitochondria where they would be oxidized [20,21]. The fact that *de novo* fatty acid synthesis in the β -cell is very low [22] indicates that malonyl-CoA is used as a switch compound, not as a precursor or effector molecule like long chain fatty acyl-CoA. The cytosolic concentration of long chain fatty acyl-CoA is controlled by feedback inhibition of acyl-CoA synthetase, and is buffered by fatty acid and long chain fatty acyl-CoA binding proteins [23]. The total concentration of long chain fatty acyl-CoA in livers of fed and fasted rats, is about 95 and 220 nmol/g dry weight, respectively [24], however quantification of cytosolic long chain fatty acyl-CoA in other tissues has yet to be done.

In contrast to the acute effect of elevated plasma FFA to enhance insulin secretion, longer-term (> 48 h) exposure results in an impaired β -cell response to glucose both *in vitro* and *in vivo* in animals [25,26] and humans [27-31]. The inhibitory effect of chronically elevated plasma FFA is more prominent in individuals with a genetic predisposition to develop type 2 diabetes [32], thus a reduction in the plasma FFA concentration in type 2 diabetes improves insulin secretion [32,33]. The term lipotoxicity describes the deleterious effect of chronic FFA elevation on insulin secretion from the pancreatic β -cell [34]. In the Zucker diabetic fatty rat, chronically increased plasma FFA levels lead initially to a physiological impairment in insulin secretion. With time, β -cell mass is reduced by more than 50 % [26]. Within the β -cell, elevated fatty acyl CoAs increase the formation of ceramide, a sphingolipid. Ceramide, in turn, augments the formation of the inducible isoform of nitric oxide, which is toxic to the β -cell [35]. Incubation of human islets with FFA or ceramide has been shown to cause β -cell apoptosis [36].

Transcriptional regulation of free fatty acid metabolism

Free fatty acid metabolism responds to varying metabolic states partially by induction of enzymes that promote either catabolic or anabolic processes. There are two major classes of transcriptional regulators of enzymes involved in fatty acid metabolism, the peroxisome proliferator-activated receptors (PPARs) and the sterol regulatory element binding proteins (SREBPs), which both exist in several isoforms. In general, PPAR γ and SREBP-1c regulate processes involved in lipogenesis whereas lipolytic enzymes are induced by PPAR α [37].

Peroxisome proliferator-activated receptors

The PPARs form a subfamily in the nuclear receptor superfamily. PPARs, like other nuclear receptors, regulate gene expression in response to specific ligands through their actions as transcription factors. Peroxisomes contain PPAR-regulated enzymes involved in fatty acid β -oxida-

tion [38]. Genetic deficiencies in peroxisome biogenesis in the human cause an accumulation of long chain fatty acids in cells [39]. So far, three isoforms encoded by separate genes and designated PPAR α , PPAR δ and PPAR γ have been identified [40].

PPAR α

PPAR α was the first member of this nuclear receptor subclass to be described. PPAR α is expressed in numerous metabolically active tissues including liver, kidney, heart, skeletal muscle, brown fat [41-43], and also in monocytes [44], vascular endothelium [45] and vascular smooth muscle cells [46].

PPAR α plays an important role in the regulation of cellular uptake, activation and β -oxidation of fatty acids. The natural, preferentially-binding ligands of PPAR α are long chain unsaturated fatty acids including arachidonic acid, linoleic acid, and oleic acid but saturated fatty acids like palmitic acid can also act as ligands [47]. In hepatocytes and other tissues where it has been studied, ligand-activated PPAR α binds to peroxisome proliferator response elements (PPRE) of DNA (Figure 2) and up-regulates transcription of genes involved in lipid catabolism and lipoprotein metabolism (Table 1) [48,49]. Consequently PPAR α serves as a long chain fatty acid sensor that leads to autoregulation of long chain fatty acid metabolism mainly in the liver and heart and to a lesser extent in muscle, thus decreasing tissue content of lipids and minimizing lipotoxicity as circulating levels fluctuate [50]. Activation of PPAR α also induces hepatic proliferation, hepatomegaly and hepatocarcinogenesis in animal [51] but not human liver [52]. Obesity is a major risk factor in the development of type 2 diabetes and PPAR α may affect body weight through regulation of fatty acid catabolism or expending energy [53]. PPAR α ligands (such as fibrate drugs) could therefore improve insulin sensitivity by reducing lipid accumulation in tissues [54].

PPAR δ

PPAR δ was initially reported as PPAR β in *Xenopus laevis* [49]. Subsequently, the receptor was cloned in the human [55] as well as in rodents [56] and was named PPAR δ . PPAR δ is expressed in a wide range of tissues and cells with the highest levels of expression found in digestive tract, heart, kidney, liver, adipose and brain [57]. Saturated and unsaturated fatty acids are natural ligands for PPAR δ [58,59]. PPAR δ is implicated in adipocyte differentiation, which is induced by long-chain fatty acids [60]. In skeletal muscle, activation of PPAR δ results in induction of proteins involved in lipid catabolism, cholesterol efflux and respiratory coupling in skeletal muscle independent from the effects of PPAR α and PPAR γ agonists [61].




Figure 2
Overview of PPAR activation and effects. FFA (eg. oleic acid) interact with PPAR, which dimerize with retinoid X receptor (RXR) and translocate to the nucleus where the complex interacts with PPRE to activate gene transcription. The general effects of transcriptional activation of PPAR α , PPAR δ and PPAR γ are shown on the right of the figure.

Table 1: Selected hepatic PPAR α regulated genes with at least one functional peroxisome proliferator receptor element (PPRE) identified within the promoter sequence

Gene	Function	Species	References
Acyl CoA binding protein	fatty acyl-CoA ester transport	rat	127
Acyl CoA oxidase	peroxisomal β -oxidation	rat, human	128-130
Apolipoprotein-AI and All	plasma HDL metabolism	human, mouse, rat	131-134
Apolipoprotein-AV	plasma triglyceride metabolism	human	134
Apolipoprotein-CIII	plasma HDL metabolism	rat	135
Bifunctional enzyme	peroxisomal β -oxidation	rat	136
Carnitine palmitoyl transferase-I and -II	mitochondrial β -oxidation	human, mouse, rat, hamster	132, 137-139
Cytochrome P450 enzymes	fatty acid and cholesterol metabolism	rat, mouse, human	130, 141-145
$\Delta 6$ - and $\Delta 5$ -desaturase	desaturation of fatty acyl-CoA	mouse	146
Fatty acid binding protein	fatty acid binding/transport	mouse	147
Fatty acid transport protein and translocase	fatty acid transport	mouse	148, 149
Lipoprotein lipase	triglyceride clearance	mouse	148, 149
Liver X receptor α	cholesterol metabolism	mouse	150, 151
Long-chain acyl-CoA synthetase	fatty acid activation	human, mouse	139, 152
Malic enzyme	fatty acid synthesis	mouse, rat	153, 154
Mitochondrial HMG-CoA synthase	ketogenesis	rat, human	152, 155
Medium-chain acyl-CoA dehydrogenase	mitochondrial β -oxidation	mouse	138, 139
Phospholipid transfer protein	HDL metabolism	human	156
Stearoyl-CoA desaturase-I	desaturation of fatty acyl CoA	mouse	157
Superoxide dismutase	free radical metabolism	rat	158
Thiolase B	mitochondrial β -oxidation	rat	159
Transferrin	iron transport	human	160
Very long- and long-chain acyl CoA dehydrogenases	mitochondrial β -oxidation	mouse	139

Abbreviations: HDL, high density lipoprotein; HMG-CoA, hydroxymethylglutaryl-Coenzyme A

PPAR γ

PPAR γ stimulates fatty acid storage in adipose tissue by increasing both the storage capacity and the fatty acid flux into adipocytes. PPAR γ is expressed in many cell types, including epithelial cells, B and T cells, macrophages, endothelial cells, smooth muscle cells [62,63] and predominantly in adipose tissue where it is necessary for the differentiation of adipocytes [64]. There are 2 splice variant of the isoform called PPAR γ 1 and γ 2; the expression distribution of PPAR γ 2 is more limited than that of PPAR γ 1 [65].

The natural ligands of PPAR γ are several unsaturated fatty acids such as oleate, linoleate, eicosapentaenoic and arachidonic acids [53]. Members of the thiazolidinedione (TZD) family, which are known as antidiabetic compounds, are synthetic ligands of PPAR γ [54]. In adipocytes, PPAR γ increases the expression of numerous genes involved in lipid metabolism and uptake [66,67]. Activation of PPAR γ also induces adipocyte apoptosis, which is restricted primarily to large fully differentiated adipocytes [68]. This pro-apoptotic effect of PPAR γ activation on large adipocytes, coupled with its capacity to enhance differentiation of adipocytes *de novo*, favours the formation of small adipocytes that tend to replace the large adipocytes normally constituting white adipose tissue [68].

PPAR γ also negatively regulates transcription of several genes that impair insulin action, including tumor necrosis factor- α (TNF α) and leptin, proinflammatory cytokines produced by adipocytes and associated with insulin resistance [69-72]. Thus, the TZD drugs lower hyperglycemia, hyperinsulinemia and hypertriglyceridemia by indirectly enhancing the sensitivity of tissues to insulin, especially in skeletal muscle. However, the function of PPAR γ is not restricted to adipogenesis and insulin sensitization. In peripheral monocytes and macrophages, PPAR γ agonists inhibit the production of inflammatory cytokines [73] and induce differentiation and apoptosis in various cancer cells [74,75].

Peroxisome proliferator-activated receptors and β -cell function

Both PPAR α and PPAR γ have been detected in pancreatic β -cells [76,77]. One caveat that complicates interpretation of some of the work described below is that PPAR α and PPAR γ agonists have effects on β -cell function independent of their interaction with the transcription factors. Thus, both fibrates and TZD can alter ATP-dependent K channel activity and rapidly (within 10 minutes) increase insulin secretion [78]. In addition, the generalized metabolic effects of these compounds may mean that effects observed *in vitro* on isolated islets may not apply to the *in vivo* situation. Therefore, the mode of delivery of the

agents (directly onto islets *versus* in diets) and the time frame of study are important considerations.

In pancreatic islets, exposure to long chain fatty acids (mixed unsaturated and saturated) induces PPAR α expression [76] whereas high glucose *in vitro* or hyperglycemia *in vivo* suppresses expression [79,80]. Artificial ligands of PPAR α such as WY14643 and clofibrate also induce PPAR α expression in rat islets [76,81,82]. Similar to hepatocytes, this leads to up-regulation of enzymes favouring lipolysis, including acyl-CoA oxidase [76,81], pyruvate dehydrogenase-4 [82] and CPT-I [76,81].

The question arises as to the role of PPAR α in the physiological regulation of insulin secretion. Its induction by long chain fatty acids and its ability to augment the insulin response to low glucose [81] suggests that it may play a role in sustaining β -cell secretory capacity during normal, cyclical periods of fasting. Thus, when glucose is low, PPAR α will be induced, favouring β -oxidation of lipids to maintain β -cell ATP at a maintenance level. Moreover, the ability of β -cells to oxidize lipids is a critical for resumption of glucose-stimulated insulin secretion at the end of the fasting period [17]. However, when glucose is elevated above basal, PPAR α will be reduced, allowing efficient glucose metabolism-dependent insulin secretion while inhibiting fatty acid oxidation. Overall, the effect of oscillating PPAR α activity inversely with glucose concentration may help to maintain glucose responsiveness of the β -cell [83]. Four-to-six-hour fasted PPAR α KO mice had normal circulating insulin [84,85] and their islets had normal glucose sensitivity [84] whereas 24 hour fasted mice had a 3-fold increase in circulating insulin [85]. The longer-term fast would allow for greater adaptation to occur; higher fasting insulin may reflect hepatic insulin resistance rather than altered β -cell function.

In addition to these postulated mechanisms of PPAR α control over β -cell glucose and lipid metabolism, it has also been proposed that amino acid metabolism might be affected. In the liver, an increase in PPAR α is associated with a decrease in amino acid catabolism [86]. Because glutamine metabolites are potential signaling molecules in the β -cell [87], PPAR α induction under conditions of low glucose could impair glucose-stimulated insulin secretion via its effects on glutamine catabolism [83]. This hypothesis has yet to be proven.

In pathophysiological conditions involving deranged glucose and lipid metabolism, altered expression of PPAR α may be important in the β -cell's lack of glucose responsiveness. In Zucker diabetic fatty rat islets, despite chronic hyperlipidemia, expression of PPAR α , acyl-CoA oxidase and CPT-I mRNA is reduced [88]. It has thus been proposed that glucose is the dominant regulator of PPAR α in

the β -cell and that its suppression is a component of glucolipotoxicity [89].

Glucolipotoxicity is a state in which β -cells are exposed to elevated plasma concentrations of both glucose and FFA, as is the case in insulin resistance. Several signalling pathways of the β -cell may be affected by altered PPAR α expression and the overall outcome is predicted to depend upon whether fat or glucose has the dominant effect. In cases where glucose is elevated relative to lipid, a chronic reduction in PPAR α would be expected to decrease the lipid oxidizing capacity of the β -cell [88,89], eliminating a detoxification route for fat metabolites [89]. Accumulation of lipids, for example as triglyceride within the β -cell, is associated with impaired glucose-stimulated insulin secretion, increased ceramide formation and apoptosis [88]. When lipid is chronically elevated relative to carbohydrate, induction of PPAR α presumably would cause strong up-regulation of fat oxidizing genes but also UCP2 (see below), which would suppress glucose-stimulated insulin secretion. The implication of these hypotheses is that either too much or too little PPAR α would impair β -cell function. Evidence in the literature supports this contention when *in vitro* models are employed. Notably, culture of islets or INS-1 cells with high glucose (6–20 mM) for 48 hours strongly suppresses PPAR α protein expression by 80%. As predicted, fatty acid oxidation and glucose-stimulated insulin secretion are attenuated, while islet triglyceride and lipid esterification are increased [79]. Conversely, induction of endogenous β -cell PPAR α (with clofibrate) leads to an increase in CPT-1 expression and fatty acid oxidation, resulting in blunted basal and glucose-stimulated insulin secretion [90]. However, the situation is less clear when experiments are performed *in vivo*, leading to the conclusion that activation of PPAR α in tissues other than β -cells causes indirect effects on insulin secretion secondary to changes in peripheral insulin sensitivity [83]. Thus, type 2 diabetic mice given dietary WY14,643, a PPAR α agonist, have normalized serum lipids, glucose and insulin. PPAR α activation also improves glucose-stimulated insulin secretion, reduces β -cell proliferation and β -cell mass compared with untreated controls [91]. Similarly, fenofibrate-treated obese diabetes-prone OLETF rats retain β -cell mass and have lower islet triglyceride content and fatty oxidation than untreated animals [92]. In both cases, the effects on β -cells are likely secondary to the observed weight loss and increase in insulin sensitivity of peripheral tissues.

Chronic induction of PPAR α may influence also insulin secretion indirectly because PPARE have been found in the promoter region of uncoupling protein-2 (UCP2) [93]. In general, uncoupling proteins (numbered 1–3 in order of their discovery) decrease metabolic efficiency by dissociating ATP synthesis from substrate oxidation in the mito-

chondrion by promoting translocation of protons from the inter-membrane space, across the inner mitochondrial membrane to the matrix [94]. Therefore, circumstances that limit mitochondrial proton gradient formation, such as up-regulation of UCP2 expression and activity, are predicted to limit insulin secretion. A study specifically examining the role of PPAR α by use of the ligand clofibrate demonstrated induction UCP2 in islets [90]. In liver, stimulation of PPAR α (or PPAR δ when PPAR α was absent) caused induction of UCP2 [95]. UCP2 expression inversely correlates with β -cell ATP and glucose-stimulated insulin secretion [96–99]. The significance of these findings is that up-regulation of UCP2 expression suppresses glucose-stimulated insulin secretion and is implicated as a potential contributor to lipotoxic effects mediated by PPAR α in β -cells.

PPAR γ may also be an important transcriptional regulator of both normal and abnormal metabolism in pancreatic β -cells. In hyperglycemic, pancreatectomized rats the expression of PPAR γ mRNA is increased [80] but others found that high fat but not high glucose up-regulates PPAR γ protein expression *in vitro* [100]. In adipocytes, PPAR γ alters the expression of fat metabolizing enzymes to increase FFA uptake into storage while simultaneously preventing the release of FFA [66,67]. However, in the β -cell some actions of PPAR γ seem to mimic those of PPAR α . Thus, one of the earliest demonstrations in islets of direct activation of PPAR γ showed that TZD caused mobilization of triglyceride and increased FFA oxidation in Zucker diabetic fatty rats [101], resulting in improved insulin secretion [101,102]. This observation has been reinforced in more recent work. Induction of PPAR γ by three different methods enhances expression of genes that participate in fatty acid oxidation [103]. Glucose-stimulated insulin secretion is enhanced by both PPAR α and γ agonists in *db/db* mice [104]. Consistent with this, mice with a partial global knockdown of PPAR γ (PPAR $\gamma^{+/-}$) on a high fat diet had blunted glucose-stimulated insulin secretion in isolated islets that was associated with an islet-specific accumulation of triglyceride [105] even though insulin resistance was partially prevented [106].

The TZD increase glucokinase and GLUT2 expression and activity via interaction with PPARE in the respective gene promoters [107,108]. A PPAR α -agonist also induced GLUT2 expression in islets but the effect on glucokinase was not documented [109]. Improved glucose metabolism, however, has not been a consistent outcome of PPAR γ induction [103]. Nonetheless, overexpression of PPAR γ in a β -cell line is detrimental to glucose-stimulated insulin secretion and proinsulin synthesis, with PPAR γ agonists causing a further negative effect [110]. Since PPAR γ was not detected in control cells, it is unclear whether these results are physiologically relevant to pri-

mary β -cell function. Interestingly, in rodent islets PPAR α is expressed at higher levels than PPAR γ [76], while in human islets the situation is reversed [111]; the functions regulated by PPAR α in rodents may be more pertinent to PPAR γ in human β -cells.

PPAR γ activation also regulates some β -cell functions that have not been ascribed to PPAR α . PPAR γ activation by TZD may relieve oxidative stress in β -cells of diabetic animals [112], leading to preservation of β -cell mass [104,112-114] and partial improvement in glucose-stimulated insulin secretion from isolated islets [112]. The potential anti-oxidative or anti-inflammatory effects of TZD in islets of type 2 diabetes models are interesting in light of reports that TZD reduce diabetes incidence in non-obese diabetic (NOD) mice [115] and more generalized inflammatory/immune responses in a variety of tissues [116]. Moreover, PPAR γ appears to be a critical determinant of β -cell expansion in response to a high fat diet [117]. However, despite these studies showing that PPAR γ exists in β -cells and that its activation can regulate gene expression and cell function, Rosen et al. [117] recently showed that the TZD's antidiabetic effects are still fully present in mice in which PPAR γ has been specifically eliminated only in β -cells. Thus, the dominant effects of dietary TZD on insulin secretion are likely indirect, a consequence of improved lipemia and glycemia.

Sterol regulatory element binding protein

The family of SREBPs governs transcriptional activation of a large number of genes involved in regulation of lipid metabolism, including lipogenesis, cholesterol transport and synthesis [118]. Of interest is the high expression of SREBP-1c in liver and adipose tissue [119], and its detection in pancreatic β -cells [120]. The primary function of SREBP-1c is to regulate transcription of genes involved in lipogenesis, such as acetyl-CoA carboxylase, fatty acid synthase and steroyl-CoA desaturase [119] and enzymes of glycolysis [118,119]. In the liver SREBP-1c appears to mediate the transcription of most insulin-responsive genes and in turn its expression, and possibly its activation, are induced by insulin [119]. Thus, SREBP-1c activity is enhanced during periods of dietary plenty; when glucose is abundant and insulin is stimulated. The outcome of SREBP-1c activation is to promote fat-sparing, leading to an increased synthesis of saturated and monounsaturated fatty acids, triglycerides and phospholipids, as well as enhanced glucose utilization via the glycolytic pathway [119]. Elevation of SREBP-1c in obesity characterized by hyperinsulinemia may therefore explain the onset of fatty liver.

SREBP-1c appears to have a similar function in lipogenesis in pancreatic β -cells as in hepatocytes, but the effects on glycolytic enzymes have received little attention. Nota-

bly, blockade of SREBP-1c expression attenuates the glucose-induced increase in acetyl-CoA carboxylase activity seen in control β -cells [121] whereas an increase in SREBP-1c induces lipogenic enzymes, triglyceride accumulation and UCP2 expression [105,122-124]. The outcome of elevated SREBP-1c is a decrease in glucose metabolism and glucose-stimulated insulin secretion in all cases. Consistent with these studies utilizing molecular manipulation of SREBP-1c expression, studies of Zucker diabetic fatty rats demonstrate increased SREBP-1c levels in islets [120]. SREBP-1c has also been implicated as a regulator of apoptosis in β -cells [122]; thus the loss of β -cell mass seen in obese-diabetic models might be related to events triggered by this transcription factor. Indeed, β -cell apoptosis might be under control of both PPAR γ and SREBP-1c because TZD has been reported to block the increase in SREBP-1c in diabetic fatty rats [120]; this implies that PPAR γ regulates SREBP-1c. Conversely, other groups have evidence that SREBP-1c can up-regulate PPAR γ mRNA expression [103,123]; thus, the relationship between these two factors is not yet clear. The UCP2 promoter has a sterol response element [124] so the negative effects of SREBP-1c on insulin secretion might be caused by its induction of UCP2. However, reducing UCP2 expression by means of a small interfering RNA only partially restored glucose-stimulated insulin secretion in SREBP-1c-overexpressing cells. Likewise, activation of the AMP-activated kinase partially rescued the phenotype of the cells with SREBP-1c induction [125]. Certainly, SREBP-1c is implicated as a key contributor to lipotoxicity, as proposed elsewhere [89,126] but further research is required to fully understand its role in regulating insulin secretion in health and diabetes.

Conclusions

FFA exert dual effects on insulin secretion, dependent on the duration of exposure. Acute exposure to FFA increase glucose-stimulated insulin secretion whereas chronic exposure attenuate glucose sensitivity of pancreatic β -cells. The coordinated control of these processes by lipid-sensing transcription factors and its relevance to β -cell dysfunction in type 2 diabetes mellitus is increasingly a subject of investigation.

PPARs (especially PPAR α and PPAR γ) are involved in the long-term regulation of lipid metabolism and their activity is modulated by endogenous lipid-derived ligands. PPAR agonists have positive effects on glucose homeostasis and lipid metabolism and can reduce cardiovascular events in obese-diabetic patients. PPAR α is a fasting lipid oxidation-glucose sparing regulator whereas PPAR γ is post-prandial lipid storing-glucose utilizing regulator. In islets, however, both PPAR α and γ appear to have some functions more consistent with PPAR α , particularly induction of lipid oxidizing enzymes, which is potentially

particularly important for maintaining basal insulin secretion. Growing evidence suggests that PPAR γ is a regulator of β -cell proliferation and that PPAR γ agonist-mediated anti-oxidative effects may also contribute to anti-diabetic activity.

SREBP-1c up-regulates lipogenic enzymes in β -cells as it does in liver. Its chronic induction in islets of obese-diabetic rodents may therefore contribute to lipotoxicity by promoting triglyceride accumulation and removing fatty-acid derived signalling factors from the cellular pool. SREBP-1c and PPAR functions appear to be closely linked through cross-talk between the pathways that control their own expression, and may function in concert to affect not only fatty acid metabolism but also glucose metabolism, β -cell proliferation and apoptosis.

Drugs given orally to activate PPARs can improve insulin sensitivity of peripheral tissues and generally appear to enhance β -cell function secondary to their insulin-sensitizing effects. However, it remains possible that specific effects on β -cells are also important contributors to the positive metabolic effects of PPAR agonists in type 2 diabetes treatment.

Declaration of Competing Interests

The author(s) declare that they have no competing interests.

Authors Contributions

ZF-H and CBC contributed equally to the writing of this review.

Acknowledgments

Research by the authors' group is supported by the Canadian Institutes for Health Research and the Canadian Diabetes Association. CBC holds a Levesque Research Chair in Nutrisciences and Health at the University of Prince Edward Island. The authors thank MB Wheeler and MC Saleh for reading the manuscript and for their helpful comments.

References

- Kutchai HC: **Digestion and absorption.** In *Principles of Physiology* Edited by: Berne RM, Levy MN. Toronto: Mosby Company; 1990:410-414.
- Oxidation of fatty acids.** In *Principles of Biochemistry* 2nd edition. Edited by: Lehninger AL, Nelson DL, Cox MM. New York: Worth Publishers Inc; 1997:479-497.
- Zimmet P, Alberti KG, Shaw J: **Global and societal implications of the diabetes epidemic.** *Nature* 2001, **414**:782-787.
- Centers for Disease Control and Prevention: *National Diabetes Fact Sheet: National estimate and general information on diabetes in the United States, 2000* Atlanta: US Department of Health and Human Services; 2003.
- DeFronzo RA: **The triumvirate: beta cell, muscle, liver. A collusion responsible for NIDDM.** *Diabetes* 1988, **37**:667-687.
- Burke JP, Williams K, Gaskill SP, Hazuda HP, Haffner SM, Stern MP: **Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study.** *Arch Intern Med* 1999, **159**:1450-1456.
- Ludvik B, Nolan JJ, Baloga J, Sacks D, Olefsky J: **Effect of obesity on insulin resistance in normal subjects and patients with NIDDM.** *Diabetes* 1995, **44**:1121-1125.
- Fraze E, Donner CC, Swislocki AL, Chiou YA, Chen YD, Reaven GM: **Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance.** *J Clin Endocrinol Metab* 1985, **61**:807-811.
- McGarry JD: **What if Minkowski had been ageusic? An alternative angle on diabetes.** *Science* 1992, **258**:766-770.
- Malaisse WJ, Best L, Kawazu S, Malaisse-Lagae F, Sener A: **The stimulus-secretion coupling of glucose-induced insulin release: fuel metabolism in islet deprived of exogenous nutrient.** *Arch Biochem Biophys* 1983, **224**:102-110.
- Hellerstrom C: **Effects of carbohydrates on the oxygen consumption of isolated pancreatic islets of mice.** *Endocrinology* 1967, **81**:105-112.
- Vara E, Tamarit-Rodriguez J: **Glucose stimulation of insulin secretion in islets of fed and starved rats and its dependence on lipid metabolism.** *Metab Clin Exp* 1986, **35**:266-271.
- Malaisse WJ: **Insulin secretion: Multifactorial regulation for a single process of release.** *Diabetologia* 1973, **9**:167-173.
- Carpinelli AR, Curi R, Malaisse WJ: **Long-term regulation of pancreatic B-cell responsiveness to D-glucose by food availability, feeding schedule and diet composition.** *Physiol Behav* 1992, **52**:1193-1196.
- Newgard CB, McGarry JD: **Metabolic coupling factors in pancreatic β cell signal transduction.** *Annu Rev Biochem* 1995, **64**:689-719.
- Warnotte C, Gilon P, Nenquin M, Henquin JC: **Mechanisms of the stimulation of insulin release by saturated fatty acids: a study of palmitate effects in mouse β -cells.** *Diabetes* 1994, **43**:703-711.
- Stein DT, Esser V, Stevenson BE, Lane KE, Whiteside JH, Daniels MB, Chen S, McGarry JD: **Essentially of circulating fatty acids for glucose-stimulated insulin secretion in fasted rats.** *J Clin Invest* 1996, **97**:2728-2735.
- McGarry JD, Dobbins RL: **Fatty acids, lipotoxicity and insulin secretion.** *Diabetologia* 1999, **42**:128-138.
- Hamilton JA, Civelek VN, Kamp F, Tornheim K, Corkey BE: **Changes in internal pH caused by movement of fatty acids into and out of clonal pancreatic β -cells (HIT).** *J Biol Chem* 1994, **269**:20852-20856.
- Matschinsky FM: **A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm.** *Diabetes* 1996, **45**:223-241.
- McGarry JD: **Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes.** *Diabetes* 2002, **51**:7-18.
- Berne C: **The metabolism of lipid in mouse pancreatic islets. The biosynthesis of triacylglycerols and phospholipids.** *Biochem J* 1975, **152**:667-673.
- Boylan JG, Hamilton JA: **Interactions of acyl-coenzyme A with phosphatidylcholine bilayers and serum albumin.** *Biochemistry* 1992, **31**:557-567.
- Corkey B: **Analysis of acyl-coenzyme A esters in biological samples.** *Methods Enzymol* 1988, **166**:55-70.
- Mason TM, Goh T, Tchipashvili V, Sandhu H, Gupta N, Lewis GF, Giacca A: **Prolonged elevation of plasma free fatty acids desensitizes the insulin secretory response to glucose in vivo in rats.** *Diabetes* 1999, **48**:524-530.
- Unger RH: **How obesity causes diabetes in Zucker diabetic fatty rats.** *Trends Endocrinol Metab* 1997, **7**:276-282.
- Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF: **Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation.** *Am J Physiol* 1999, **276**:E1055-E1066.
- Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF: **Prolonged elevation of plasma free fatty acids impairs pancreatic B-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes.** *Diabetes* 2000, **49**:399-408.
- Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K: **Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes.** *Am J Physiol Endocrinol Metab* 2004, **287**:E537-E546.
- Paolisso G, Gambardella A: **Opposite effects of short and long-term fatty acid infusion on insulin secretion in healthy subjects.** *Diabetologia* 1995, **38**:1295-1299.
- Stefan N, Fritsche A, Haring H, Stumvoll M: **Effect of experimental elevation of free fatty acids on insulin secretion and insulin**

- sensitivity in healthy carriers of the Pro12 Ala polymorphism of the peroxisome proliferator-activated receptor γ 2 gene. *Diabetes* 2001, **50**:1143-1148.
32. Paolisso G, Tagliamonte MR, Rizzo MR, Gualdiero P, Saccomanno F, Gambardella A, Giugliano D, D'Onofrio F, Howard BV: **Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes.** *Diabetologia* 1998, **41**:1127-1132.
 33. Qvigstad E, Mostad IL, Bjerve KS, Grill VE: **Acute lowering of circulating fatty acids improves insulin secretion in a subset of type 2 diabetes subjects.** *AM J Physiol Endocrinol Metab* 2003, **284**:E129-E137.
 34. Unger RH: **Lipotoxic diseases.** *Annu Rev Med* 2002, **53**:319-336.
 35. Shimabukuro M, Zhou YT, Levi M, Unger RH: **Fatty acid induced β -cell apoptosis: a link between diabetes and obesity.** *Proc Natl Acad Sci USA* 1998, **95**:2498-2502.
 36. Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, Di Mario U, Del Prato S, Marchetti P: **Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: Evidence that cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.** *Diabetes* 2002, **51**:1437-1442.
 37. Kersten S: **Effects of fatty acids on gene expression: role of peroxisome proliferator-activated receptor α , liver X receptor α and sterol regulatory element-binding protein-1 c.** *Proc Nutr Soc* 2002, **61**:371-374.
 38. Reddy JK, Chu R: **Peroxisome proliferator-induced pleiotropic responses: Pursuit of a phenomenon.** *Ann NY Acad Sci* 1996, **804**:176-201.
 39. Goldfischer SL: **Peroxisomal diseases.** *Prog Clin Biol Res* 1988, **282**:117-137.
 40. Rosen ED, Spiegelman BM: **PPAR γ : a nuclear regulator of metabolism, differentiation, and cell growth.** *J Biol Chem* 2001, **276**:37731-37734.
 41. Sher T, Yi H-F, McBride OW, Gonzalez FJ: **cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor.** *Biochemistry* 1993, **32**:5598-5604.
 42. Braissant O, Foulfelle F, Scotto C, Dauca M, Wahli W: **Differential expression of peroxisome proliferator activated receptor (PPARs): tissue distribution of PPAR- α , - β and - γ in the adult rat.** *Endocrinology* 1996, **137**:354-366.
 43. Auboeuf D, Rieusset J, Fajas L, Vallier P, Frering V, Riou JP, Staels B, Auwerx J, Laville M, Vidal H: **Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor α in humans.** *Diabetes* 1997, **46**:1319-1327.
 44. Chinetti G, Griglio S, Antonucci M, Torra IP, Delerive P, Majd Z, Fruchart JC, Chapman J, Najib J, Staels B: **Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages.** *J Biol Chem* 1998, **273**:25573-25580.
 45. Inoue I, Shino K, Noji S, Awata T, Katayama S: **Expression of peroxisome proliferator-activated receptor α in primary cultures of human vascular endothelial cells.** *Biochem Biophys Res Commun* 1998, **246**:370-374.
 46. Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A: **Activation of human aortic smooth-muscle cells is inhibited by PPAR α but not PPAR γ activators.** *Nature* 1998, **393**:790-793.
 47. Gottlicher M, Widmark E, Li Q, Gustafsson JA: **Fatty acids activate a chimera of the clofibrilic acid-activated receptor and the glucocorticoid receptor.** *Proc Natl Acad Sci USA* 1992, **89**:4653-4657.
 48. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J: **Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR α and PPAR γ activators.** *J Biol Chem* 1997, **272**:28210-28217.
 49. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W: **Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors.** *Cell* 1992, **68**:879-887.
 50. Kersten S: **Peroxisome proliferator activated receptors and obesity.** *Eur J Pharmacol* 2002, **440**:223-234.
 51. Issemann I, Green S: **Activation of a member of the steroid hormone receptor superfamily by some peroxisome proliferators.** *Nature* 1990, **347**:645-649.
 52. Cattley RC, DeLuca J, Elcombe C, Fenner-Crisp P, Lake BG, Marsman DS, Pastoor TA, Popp JA, Robinson DE, Schwetz B, Tugwood J, Wahli W: **Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?** *Regul Toxicol Pharmacol* 1998, **27**:47-60.
 53. Desvergne B, Wahli W: **Peroxisome proliferator-activated receptors: nuclear control of metabolism.** *Endocr Rev* 1999, **20**:649-688.
 54. Verges B: **Clinical interest of PPAR ligands. Particular benefit in type 2 diabetes and metabolic syndrome.** *Diabetes Metab* 2004, **30**:7-12.
 55. Schmidt A, Endo N, Rutledge SJ, Vogel R, Shinar D, Rodan GA: **Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acid.** *Mol Endocrinol* 1992, **6**:1634-1641.
 56. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, Evans RM: **Differential expression and activation of a family of murine peroxisome proliferator-activated receptors.** *Proc Natl Acad Sci USA* 1994, **91**:7355-7359.
 57. Escher P, Braissant O, Basu-Modak S, Michalik L, Wahli W, Desvergne B: **Rat PPARs: quantitative analysis in adult rat tissues and regulation in fasting and refeeding.** *Endocrinology* 2001, **142**:4195-4202.
 58. Bastie C, Holst D, Gaillard D, Jehl-Pietri C, Grimaldi PA: **Expression of peroxisome proliferator-activated receptor PPAR δ promotes induction of PPAR γ and adipocyte differentiation in 3T3C2 fibroblasts.** *J Biol Chem* 1999, **274**:21920-21925.
 59. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV: **Molecular recognition of fatty acids by peroxisome proliferator-activated receptors.** *Mol Cell* 1999, **3**:397-403.
 60. Gaw A, Packard CJ, Shepherd J: **Fibrates.** *Handb Exp Pharmacol* 1994, **109**:325-48.
 61. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE: **The peroxisome proliferator-activated receptor β/δ agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.** *Mol Endocrinol* 2003, **17**:2477-2493.
 62. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: **Expression and function of PPAR γ in rat and human vascular smooth muscle cells.** *Circulation* 2000, **101**:1311-1318.
 63. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ: **The nuclear receptor PPAR γ and immunoregulation. PPAR γ mediates inhibition of helper T cell responses.** *J Immunol* 2000, **164**:1364-1371.
 64. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spiegelman BM, Mortensen RM: **PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro.** *Mol Cell* 1999, **4**:611-617.
 65. Vidal-Puig A, Jimenez-Linan M, Lowell BB, Hamann A, Hu E, Spiegelman B, Flier JS, Moller DE: **Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.** *J Clin Invest* 1996, **97**:2553-61.
 66. Tontonoz P, Hu E, Spiegelman BM: **Regulation of adipocyte gene expression and differentiation by peroxisome proliferator activated receptor γ .** *Curr Opin Genet Dev* 1995, **5**:571-576.
 67. Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J: **Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPAR α and PPAR γ activators.** *J Biol Chem* 1997, **272**:28210-28217.
 68. Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T: **Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.** *J Clin Invest* 1998, **101**:1354-1361.
 69. Hotamisligil GS, Shargill NS, Spiegelman BM: **Adipose expression of tumor necrosis factor- α : Direct role in obesity-linked insulin resistance.** *Science* 1993, **259**:87-91.
 70. Walczak R, Tontonoz P: **PPARadigms and PPARadoxes: expanding roles for PPAR γ in the control of lipid metabolism.** *J Lipid Res* 2002, **43**:177-186.

71. Kallen CB, Lazar MA: **Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes.** *Proc Natl Acad Sci USA* 1996, **93**:5793-5796.
72. De Vos P, Lefebvre AM, Miller SG, Guerre-Millo M, Wong KM, Saladin R, Hamann LG, Staels B, Briggs MR, Auwerx J: **Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor γ .** *J Clin Invest* 1996, **98**:1004-1009.
73. Jiang C, Ting AT, Seed B: **PPAR γ agonists inhibit production of monocyte inflammatory cytokines.** *Nature* 1998, **391**:82-86.
74. Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP: **Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.** *Proc Natl Acad Sci USA* 1998, **95**:8806-8811.
75. Gimble JM, Pighetti GM, Lerner MR, Wu X, Lightfoot SA, Brackett DJ, Darcy K, Hollingsworth AB: **Expression of peroxisome proliferator-activated receptor mRNA in normal and tumorigenic mammary glands.** *Biochem Biophys Res Commun* 1998, **253**:813-817.
76. Zhou Y-T, Shimabukuro M, Wang M-Y, Lee Y, Higa M, Milburn JL, Newgard CB, Unger RH: **Role of peroxisome proliferator-activated receptor α in disease of pancreatic β cells.** *Proc Natl Acad Sci USA* 1998, **95**:8898-8903.
77. Dubois M, Paltou F, Kerr-Conte J, Gyr V, Vandewalle B, Desreumaux P, Auwerx J, Schoonjans K, Lefebvre J: **Expression of peroxisome proliferator-activated receptor γ in normal human pancreatic islet cells.** *Diabetologia* 2000, **43**:1165-1169.
78. Shimomura K, Shimizu H, Ikeda M, Okada S, Kakei M, Matsumoto S, Mori M: **Fenofibrate, troglitazone, and 15-deoxy- Δ 12, 14-prostaglandin J2 close K_{ATP} channels and induce insulin secretion.** *J Pharmacol Exp Ther* 2004, **310**:1273-1280.
79. Roduit R, Morin J, Masse F, Segall L, Roche E, Newgard CB, Assimakopoulos-Jeannet F, Prentki M: **Glucose down-regulates the expression of the peroxisome proliferator-activated receptor- α gene in the pancreatic β -cell.** *J Biol Chem* 2000, **275**:35799-35806.
80. Laybutt R, Hasenkamp W, Groff A, Grey S, Jonas JC, Kaneto H, Sharma A, Bonner-Weir S, Weir G: **Beta-cell adaptation to hyperglycemia.** *Diabetes* 2001, **50**(Suppl 1):S180-S181.
81. Yoshikawa H, Tajiri Y, Sako Y, Hashimoto T, Umeda F, Nawata H: **Effects of free fatty acids on beta-cell functions: a possible involvement of peroxisome proliferator-activated receptors alpha or pancreatic/duodenal homeobox.** *Metabolism* 2001, **50**:613-618.
82. Sugden MC, Bulmer K, Augustine D, Holness MJ: **Selective modification of pyruvate dehydrogenase kinase isoform expression in rat pancreatic islets elicited by starvation and activation of peroxisome proliferator-activated receptor- α : implications for glucose-stimulated insulin secretion.** *Diabetes* 2001, **50**:2729-2736.
83. Sugden MC, Holness MJ: **Potential role of peroxisome proliferator-activated receptor- α in the modulation of glucose-stimulated insulin secretion.** *Diabetes* 2004, **53**(Suppl 1):S71-S81.
84. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B: **PPAR- α -null mice are protected from high-fat diet-induced insulin resistance.** *Diabetes* 2001, **50**:2809-2814.
85. Sugden MC, Bulmer K, Gibbons GF, Knight BL, Holness MJ: **Peroxisome-proliferator-activated receptor- α (PPAR α) deficiency leads to dysregulation of hepatic lipid and carbohydrate metabolism by fatty acids and insulin.** *Biochem J* 2002, **364**:361-368.
86. Kersten S, Mandard S, Escher P, Gonzalez FJ, Tafuri S, Desvergne B, Wahli W: **The peroxisome proliferator-activated receptor alpha regulates amino acid metabolism.** *FASEB J* 2001, **15**:1971-1978.
87. Maechler P, Wollheim CB: **Mitochondrial glutamate acts as a messenger in glucose-induced insulin exocytosis.** *Nature* 1999, **402**:685-689.
88. Unger RH, Orci L: **Lipoapoptosis: its mechanism and its diseases.** *Biochim Biophys Acta* 2002, **1585**:202-212.
89. Prentki M, Joly E, El-Assaad W, Roduit R: **Malonyl-CoA signaling, lipid partitioning, and glucolipototoxicity. Role in β -cell adaptation and failure in the etiology of diabetes.** *Diabetes* 2002, **51**(Suppl 3):S405-S413.
90. Tordjman K, Standley KN, Bernal-Mizrachi C, Leone TC, Coleman T, Kelly DP, Semenkovich CF: **PPAR α suppresses insulin secretion and induces UCP2 in insulinoma cells.** *J Lipid Res* 2002, **43**:936-943.
91. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D: **Peroxisome proliferator-activated receptor- α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis.** *Diabetes* 2003, **52**:1770-1778.
92. Koh EH, Kim M-S, Park J-Y, Kim HS, Youn J-Y, Park H-S, Youn JH, Lee K-U: **Peroxisome proliferator-activated receptor (PPAR)- α activation prevents diabetes in OLETF rats. Comparison with PPAR- γ activation.** *Diabetes* 2003, **52**:2331-2337.
93. Kelly LJ, Vicario PP, Thompson GM, Candelore MR, Doebber TW, Ventre J, Wu MS, Meurer R, Forrest MJ, Conner MW, Cascieri MA, Molle DE: **Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression.** *Endocrinology* 1998, **139**:4920-4927.
94. Schrauwen P, Hesselink M: **UCP2 and UCP3 in muscle controlling body metabolism.** *J Exp Biol* 2002, **205**:2275-85.
95. Grav HJ, Tronstad KJ, Gudbrandsen OA, Berge K, Fladmark KE, Martinsen TC, Waldum H, Wergedahl H, Berge RK: **Changed energy state and increased mitochondrial beta-oxidation rate in liver of rats associated with lowered proton electrochemical potential and stimulated uncoupling protein 2 (UCP-2) expression: evidence for peroxisome proliferator-activated receptor-alpha independent induction of UCP-2 expression.** *J Biol Chem* 2003, **278**(33):30525-33.
96. Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F, Tushima RG, Pennfather PS, Salapatek AM, Wheeler MB: **Increased uncoupling protein-2 levels in beta cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action.** *Diabetes* 2001, **50**:1302-1310.
97. Hong Y, Fink BD, Dillon JS, Sivitz W: **Effects of adenoviral over-expression of uncoupling protein-2 and -3 on mitochondrial respiration in insulinoma cells.** *Endocrinology* 2001, **142**:249-56.
98. Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB: **Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction and type 2 diabetes.** *Cell* 2001, **105**:745-55.
99. Joseph JW, Koshkin V, Zhang CY, Wang J, Lowell BB, Chan CB, Wheeler MB: **Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high fat diet.** *Diabetes* 2002, **51**:3211-3219.
100. Patane G, Anello M, Piro S, Vigneri R, Purrello F, Rabuazzo AM: **Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-activated receptor- γ inhibition.** *Diabetes* 2002, **51**:2749-2756.
101. Shimabukuro M, Zhou Y-T, Lee Y, Unger RH: **Induction of uncoupling protein-2 mRNA by troglitazone in the pancreatic islets of Zucker diabetic fatty rats.** *Biochem Biophys Res Commun* 1997, **237**:359-361.
102. Sreenan S, Sturis J, Pugh W, Burant CF, Polonsky KS: **Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.** *Am J Physiol* 1996, **271**:E742-E747.
103. Parton LE, Diraison F, Neill SE, Ghosh SK, Rubino MA, Bisi JE, Briscoe CP, Rutter GA: **Impact of PPAR γ overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays.** *Am J Physiol Endocrinol Metab* 2004, **287**:E390-E404.
104. Yajima K, Hirose H, Fujita H, Seto Y, Fujita H, Ukeda K, Miyashita K, Kawai T, Yamamoto Y, Ogawa T, Yamada T, Saruta T: **Combination therapy with PPAR γ and PPAR α agonists increases glucose-stimulated insulin secretion in db/db mice.** *Am J Physiol Endocrinol Metab* 2003, **284**:E966-E971.
105. Eto K, Yamashita T, Matsui J, Terauchi Y, Noda M, Kadowaki T: **Genetic manipulation of fatty acid metabolism in β -cells are**

- associated with dysregulated insulin secretion. *Diabetes* 2002, **51**(Suppl 3):S414-S420.
106. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Nagai R, Tobe K, Kimura S, Kadowaki T: **PPAR- γ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance.** *Mol Cell* 1999, **4**:597-609.
 107. Kim HI, Cha JY, Kim SY, Kim JW, Roh KJ, Seong JK, Lee NT, Choi KY, Kim KS, Ahn YH: **Peroxisomal proliferator-activated receptor-gamma upregulates glucokinase gene expression in beta-cells.** *Diabetes* 2002, **51**:676-685.
 108. Kim HI, Kim JW, Kim SH, Cha JY, Kim AS, Ahn YH: **Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter.** *Diabetes* 2000, **49**:1517-1524.
 109. Wang Z, Gleichmann H: **Glut2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice.** *Diabetes* 1998, **47**:50-56.
 110. Nakamichi Y, Kikuta T, Ito E, Ohara-Imaizumi M, Nishiwaki C, Ishida H, Nagamatsu S: **PPAR- γ overexpression suppresses glucose-induced proinsulin biosynthesis and insulin release synergistically with pioglitazone in MIN6 cells.** *Biochem Biophys Res Commun* 2003, **306**:832-836.
 111. Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S: **Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPAR γ 2 in the modulation of insulin secretion.** *Am J Physiol Endocrinol Metab* 2003, **286**:E560-E567.
 112. Ishida H, Takizawa M, Ozawa S, Nakamichi Y, Yamaguchi S, Katsuta H, Tanaka T, Maruyama M, Katahira H, Yoshimoto K, Itagaki E, Nagamatsu S: **Pioglitazone improves insulin secretory capacity and prevents the loss of β -cell mass in obese diabetic db/db mice: possible protection of β -cells from oxidative stress.** *Metabolism* 2004, **53**:488-494.
 113. Diani AR, Sawada G, Wyse B, Marray FT, Khan M: **Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes.** *Am J Physiol Endocrinol Metab* 2003, **286**:E116-E122.
 114. Higa M, Zhou Y-T, Ravazzola M, Baetens D, Orzi L, Unger RH: **Troglitazone prevents mitochondrial alterations, β cell destruction and diabetes in obese prediabetic rats.** *Proc Natl Acad Sci USA* 1999, **96**:11513-11518.
 115. Beales PE, Liddi R, Giorgini AE, Signore A, Procaccini E, Batchelor K, Pozzilli P: **Troglitazone prevents insulin dependent diabetes in the non-obese diabetic mouse.** *Eur J Pharmacol* 1998, **357**:221-225.
 116. Pershadsingh HA: **Peroxisome proliferator-activated receptor- γ : therapeutic target for diseases beyond diabetes: quo vadis?** *Expert Opin Investig Drugs* 2004, **13**:215-228.
 117. Rosen ED, Kulkarni RN, Sarraf P, Ozcan U, Okada T, Hsu C-H, Eisenman D, Magnuson MA, Gonzalez FJ, Kahn CR, Spiegelman BM: **Targeted elimination of peroxisome proliferator-activated receptor γ in β cells leads to abnormalities in islet mass without compromising glucose homeostasis.** *Mol Cell Biol* 2003, **23**:7222-7229.
 118. Foufelle F, Ferre P: **New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c.** *Biochem J* 2002, **366**:377-391.
 119. Horton JD, Goldstein JL, Brown MS: **SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.** *J Clin Invest* 2002, **109**:1125-1131.
 120. Kakuma T, Lee Y, Higa M, Wang Z, Pan W, Shimomura I, Unger RH: **Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets.** *Proc Natl Acad Sci USA* 2000, **97**:8536-8541.
 121. Andreolas C, da Silva Xavier G, Diraison F, Zhao C, Varadi A, Lopez-Casillas F, Ferre P, Foufelle F, Rutter GA: **Stimulation of acetyl-CoA carboxylase gene expression by glucose requires insulin release and sterol regulatory element binding protein 1c in pancreatic MIN6 beta-cells.** *Diabetes* 2002, **51**:2536-2545.
 122. Wang H, Maechler P, Antinozzi PA, Herrero L, Hagenfeldt-Johansson KA, Bjorklund A, Wollheim CB: **The transcription factor SREBP-1c is instrumental in the development of beta-cell dysfunction.** *J Biol Chem* 2003, **278**:16622-16629.
 123. Diraison F, Parton L, Ferre P, Foufelle F, Briscoe CP, Leclerc I, Rutter GA: **Over-expression of sterol-regulatory element-binding protein-1c (SREBP1c) in rat pancreatic islets induces lipogenesis and decreases glucose-stimulated insulin release: modulation by 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR).** *Biochem J* 2004, **378**:769-778.
 124. Medvedev AV, Robidoux J, Bai X, Cao W, Floering LM, Daniel KW, Collins S: **Regulation of the uncoupling protein-2 gene in INS-1 β -cells by oleic acid.** *J Biol Chem* 2002, **277**:42639-42644.
 125. Yamashita T, Eto K, Okazaki Y, Yamashita S, Yamauchi T, Sekine N, Nagai R, Noda M, Kadowaki T: **Role of uncoupling protein-2 up-regulation and triglyceride accumulation in impaired glucose-stimulated insulin secretion in a β -cell lipotoxicity model overexpressing sterol regulatory element binding protein-1c.** *Endocrinology* 2004, **145**:3566-3577.
 126. Poitout V: **β -cell lipotoxicity: burning fat into heat?** *Endocrinology* 2004, **145**:3563-3565.
 127. Elholm M, Bjerking G, Knudsen J, Kristiansen K, Mandrup S: **Regulatory elements in the promoter region of the rat gene encoding the acyl-CoA-binding protein.** *Gene* 1996, **173**:233-238.
 128. Devchand PR, Keller H, Peters JM, Vazquez M, Gonzalez FJ, Wahli W: **The PPAR α -leukotriene B4 pathway to inflammation control.** *Nature* 1996, **384**:39-43.
 129. Varanasi U, Chu R, Huang Q, Castellon R, Yeldandi AV, Reddy JK: **Identification of a peroxisome proliferator-responsive element upstream of the human peroxisomal fatty acyl coenzyme A oxidase gene.** *J Biol Chem* 1996, **271**:2147-2155.
 130. Karam WG, Ghanayem BI: **Induction of replication DNA synthesis and PPAR α -dependent gene transcription by Wy-14643 in primary rat hepatocyte and non-parenchymal cell co-cultures.** *Carcinogenesis* 1997, **18**:2077-2083.
 131. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Deneffe P, Staels B, Branellec D: **Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice.** *J Clin Invest* 1996, **97**:2408-2416.
 132. Raspe E, Madsen L, Lefebvre AM, Leitersdorf I, Gelman L, Peinado-Onsurbe J, Dallongeville J, Fruchart JC, Berge R, Staels B: **Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid (TTA) via PPAR α activation.** *J Lipid Res* 1999, **40**:2099-2110.
 133. Vu-Dac N, Schoonjans K, Kosykh V, Dallongeville J, Fruchart JC, Staels B, Auwerx J: **Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.** *J Clin Invest* 1995, **96**:741-750.
 134. Prieur X, Coste H, Rodriguez JC: **The human apolipoprotein AV gene is regulated by PPAR α and contains a novel FXR response element.** *J Biol Chem* 2003, **278**:25468-25480.
 135. Hertz R, Bishara-Shieban J, Bar-Tana J: **Mode of action of peroxisome proliferators as hypolipidemic drugs. Suppression of apolipoprotein C-III.** *J Biol Chem* 1995, **270**:13470-13475.
 136. Nicolas-Frances V, Dasari VK, Abruzzi E, Osumi T, Latruffe N: **The peroxisome proliferator response element (PPRE) present at positions-681/-669 in the rat liver 3-ketoacyl-CoA thiolase B gene functionally interacts differently with PPAR α and HNF-4.** *Biochem Biophys Res Commun* 2000, **269**:347-351.
 137. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W: **Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting.** *J Clin Invest* 1999, **103**:1489-1498.
 138. Leone TC, Weinheimer CJ, Kelly DP: **A critical role for the peroxisome proliferator-activated receptor α in the cellular fasting response: the PPAR α -null mouse as a model of fatty acid oxidation disorders.** *Proc Natl Acad Sci USA* 1999, **96**:7473-7478.
 139. Aoyama T, Peters JM, Iritani N, Nakajima T, Furihata K, Hashimoto T, Gonzalez FJ: **Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor α .** *J Biol Chem* 1998, **273**:5678-5684.
 140. Minnick A, Tian N, Byan L, Bilder G: **A potent PPAR α agonist stimulates mitochondrial fatty acid β -oxidation in liver and skeletal muscle.** *Am J Physiol Endocrinol Metab* 2001, **280**:E270-E279.
 141. Kroetz DL, Yook P, Costet P, Bianchi P, Pineau T: **Peroxisome proliferator-activated receptor α controls the hepatic CYP4A**

- induction adaptive response to starvation and diabetes. *J Biol Chem* 1998, **273**:31581-31589.
142. Aldridge TC, Tugwood JD, Green S: **Identification and characterization of DNA elements implicated in the regulation of CYP4A1 transcription.** *Biochem J* 1995, **306**:473-479.
 143. Yu S, Cao WQ, Kashireddy P, Meyer K, Jia Y, Hughes DE, Tan Y, Feng J, Yeldandi AV, Rao MS, Costa RH, Gonzalez FJ, Reddy JK: **Human peroxisome proliferator-activated receptor α supports the induction of peroxisome proliferation in PPAR α -deficient mouse liver.** *J Biol Chem* 2001, **276**:42485-42491.
 144. Patel DD, Knight BL, Soutar AK, Gibbons GF, Wade DP: **The effect of peroxisome-proliferator-activated receptor- α on the activity of the cholesterol 7 α -hydroxylase gene.** *Biochem J* 2000, **351**:747-753.
 145. Cheema SK, Agellon LB: **The murine and human cholesterol 7 α -hydroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferator-activated receptor α .** *J Biol Chem* 2000, **275**:12530-12536.
 146. Guillou H, Martin P, Jan S, D'Andrea S, Roulet A, Catheline D, Rioux V, Pineaut T, Legrand P: **Comparative effect of fenofibrate on hepatic desaturases in wild-type and peroxisome proliferator-activated receptor α -deficient mice.** *Lipids* 2002, **37**:981-989.
 147. Wolfrum C, Ellinghaus P, Fobker M, Seedorf U, Assmann G, Borchers T, Spener F: **Phytanic acid is ligand and transcriptional activator of muring liver fatty acid binding protein.** *J Lipid Res* 1999, **40**:708-714.
 148. Motojima K, Passilly P, Peters JM, Gonzalez FJ, Latruffe N: **Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor α and γ activators in a tissue- and inducer-specific manner.** *J Biol Chem* 1998, **273**:16710-16714.
 149. Yamazaki K, Kuromitsu J, Tanaka I: **Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor α agonists.** *Biochem Biophys Res Commun* 2002, **290**:1114-1122.
 150. Kok T, Wolters H, Bloks W, Havinga R, Jansen PL, Staels B, Kuipers F: **Induction of hepatic ABC transporter expression is part of the PPAR α -mediated fasting response in the mouse.** *Gastroenterology* 2003, **124**:160-171.
 151. Tobin KA, Steineger HH, Alberti S, Spydevold O, Auwerx J, Gustafsson JA, Nebb HI: **Cross talk between fatty acid and cholesterol metabolism mediated by liver X receptor- α .** *Mol Endocrinol* 2000, **14**:741-752.
 152. Hsu MH, Savas U, Griffin KJ, Johnson EF: **Identification of peroxisome proliferator-responsive human genes by elevated expression of the peroxisome proliferator-activated receptor α in HepG2 cells.** *J Biol Chem* 2001, **276**:27950-27958.
 153. Shin M, Ohnishi M, Iguchi S, Sano K, Umezawa C: **Peroxisome-proliferator regulates key enzymes of the tryptophan-NAD⁺ pathway.** *Toxicol Appl Pharmacol* 1999, **158**:71-80.
 154. Wan YJ, Cai Y, Lungo W, Fu P, Locker J, French S, Sucov HM: **Peroxisome proliferator-activated receptor α -mediated pathways are altered in hepatocyte-specific retinoid X receptor α -deficient mice.** *J Biol Chem* 2000, **275**:28285-28290.
 155. Hegardt FG: **Transcriptional regulation of mitochondrial HMG-CoA synthase in the control of ketogenesis.** *Biochimie* 1998, **80**:803-806.
 156. Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: **Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate.** *J Biol Chem* 2001, **276**:25841-25847.
 157. Miller CV, Ntambi JM: **Peroxisome proliferators induce mouse liver stearoyl-CoA desaturase I gene expression.** *Proc Natl Acad Sci USA* 1996, **93**:9443-9448.
 158. Yoo HY, Chang MS, Rho HM: **Induction of the rat Cu/Zn superoxide dismutase gene through the peroxisome proliferator-responsive element by arachidonic acid.** *Gene* 1999, **234**:87-91.
 159. Latruffe N, Nicolas-Frances V, Dasari VK, Osumi T: **Studies on regulation of the peroxisomal beta-oxidation at the 3-ketothiolase step. Dissection of the rat liver thiolase B gene promoter.** *Adv Exp Med Biol* 1999, **466**:253-259.
 160. Hertz R, Seckbach M, Zakin MM, Bar-Tana J: **Transcriptional suppression of the transferrin gene by hypolipidemic peroxisome proliferators.** *J Biol Chem* 1996, **271**:218-224.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

